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Summary Background AZD4547 is a potent, oral, highly se-
lective fibroblast growth factor receptor (FGFR) inhibitor in
clinical development for treating tumours with a range of
FGFR aberrations, including FGFR mutations, amplifications
and fusions. Methods This open-label, Phase I, multicentre
study (NCT01213160) evaluated the safety, pharmacokinetics,
and preliminary antitumour efficacy (RECIST v1.1) of
AZD4547 monotherapy in Japanese patients with advanced
solid tumours. Part Awas a dose-escalation part; Part B was a
dose-expansion part in patients with FGFR-amplified tumours,
confirmed by fluorescence in situ hybridization. Results Thirty
patients enrolled in Part A (dose range: 40 mg twice daily [bid]
to 120 mg bid; 160 mg once daily [qd]), four in Part B (80 mg
bid). No dose-limiting toxicities were observed and maximum
tolerated dose was not determined. Most common adverse
events (AEs; any grade) were: dysgeusia (50% of patients);
stomatitis (41%); diarrhoea (38%); hyperphosphataemia
(38%); dry mouth (35%). Common grade ≥3 AEs were nausea
(12% of patients) and neutropenia (9%). No complete or par-
tial responses were observed: 21/30 patients had stable disease
≥4 weeks in Part A, and 1/4 patients had stable disease
≥10 weeks in Part B. Following single and multiple dosing,
absorption rate appeared moderate; peak plasma concentra-
tions generally occurred 3–4 h post-dose, then declined
biphasically with terminal half-life ~30 h. Steady state was
reached by day 8. Compared with single dosing, plasma con-
centrations were, on average, 2.4- and 3.3- to 5.4-fold higher
after qd and bid dosing, respectively. Conclusions AZD4547
was well tolerated in Japanese patients, with best response of
stable disease ≥4 weeks.
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Introduction
Fibroblast growth factor receptors (FGFRs) are transmembrane
receptor tyrosine kinases with varied biological roles in regu-
lating angiogenesis, cell proliferation, differentiation, migration
and survival. Altered FGFR signalling has the potential to drive
mitogenic, invasive, anti-apoptotic and pro-angiogenic cells
and has been increasingly implicated in a range of solid tumour
types, including breast cancer (BC), high-grade bladder cancer,
non-small-cell lung cancer (NSCLC) and gastric cancer (GC),
as well as haematological malignancies. Of the five known
FGFRs found in humans, FGFR1–4 are characterized by extra-
cellular immunoglobulin-like and intracellular tyrosine kinase
domains, whereas the atypical FGFR5 (also known as fibro-
blast growth factor receptor-like 1) lacks the cytoplasmic tyro-
sine kinase domain; consequently, its role is less understood.
There are several mechanisms underlying the misregulation of
FGFRs in neoplastic disease, including activating mutations in
FGFRs [1, 2], FGFR gene amplification [2–6], FGFR chromo-
somal translocations [7–9], alternative splicing of FGFRs [10],
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and altered autocrine and paracrine signalling at FGFRs via
FGF [2].
AZD4547 is a potent, oral, highly selective inhibitor of
FGFR1–3 with proven antitumour properties from preclinical
studies [11–15], including work in FGFR2-amplified GC xe-
nografts that demonstrated complete and prolonged tumour
regression in several AZD4547-treated animals [12]. An ini-
tial Phase I study in a Western population indicated that
AZD4547 monotherapy has an acceptable safety profile in
patients with several tumour types (NCT00979134). During
this study, a partial response (PR) was observed following
AZD4547 treatment in a patient with FGFR1-amplified squa-
mous NSCLC. Stable disease was experienced by 4/21 addi-
tional patients (19.0%), three of whom had confirmed FGFR
amplification status (squamous NSCLC, n=1; bladder cancer,
n=1; BC, n=1) [16]. These data suggest a potential associa-
tion between FGFR amplification status and clinical benefit
with AZD4547 therapy.
It is thought that FGFRs mediate angiogenesis through
their synergistic role with vascular endothelial growth factor
receptors (VEGFRs). The success of bevacizumab, a mono-
clonal antibody that became the first approved anti-VEGF
therapy, has given rise to several anti-angiogenic therapies,
most notably, a group of oral tyrosine kinase inhibitors
(TKIs) targeting VEGFR. Although these drugs, which in-
clude sunitinib [17, 18], sorafenib [19–22], pazopanib [23,
24] and cediranib [25–28], have demonstrated promising re-
sults in patients with advanced cancer, resistance generally
develops following an initial clinical response, and patients
experience relapse. Preclinical data have demonstrated that
tumours with resistance to anti-VEGF therapies can over-
express FGFs, and there is clinical evidence indicating that
disease progression following bevacizumab treatment is pre-
ceded by an increase in levels of basic FGF (bFGF) [29, 30].
Elevated bFGF levels were also significantly associated with
shorter overall survival in cediranib-treated patients [30, 31].
These data suggest that inhibition of FGFRs, together with
direct antitumour activity, may play a role in preventing resis-
tance to anti-angiogenic drugs [29].
This Phase I study (NCT01213160) was designed to eval-
uate the safety and tolerability, appropriate dosing, pharmaco-
kinetic (PK) profile, and preliminary antitumour effects of




Eligible patients had confirmed solid malignancies for which
standard therapies did not exist or were no longer effective, a
World Health Organization (WHO) performance status of 0–
1, and a life expectancy of at least 12 weeks. Previous preclin-
ical data have revealed pharmacodynamic effects on cartilage
and growing bones following treatment with another FGFR
inhibitor [32]. In order to ensure that maturation of the skele-
ton is complete upon entry into this study, eligible patients
must be aged ≥25 years. Exclusion criteria included: any che-
motherapy, immunotherapy, or anticancer agents ≤3 weeks
prior to study entry; major surgery or radiotherapy ≤4 weeks
prior to study entry; nitrosourea or mitomycin C ≤6 weeks
prior to study entry; any unresolved toxicities from previous
treatments exceeding Common Terminology Criteria for
Adverse Events (CTCAE) grade 1 (excluding alopecia).
Specific cardiac- and ophthalmologically related exclusion
criteria included: clinically important electrocardiogram
(ECG) abnormalities; QT interval ≥470 ms; history or evi-
dence of retinal pigmented epithelial detachment; history or
evidence of age-related macular degeneration. Other exclu-
sion criteria included: spinal cord compression; brain metas-
tases; severe or uncontrolled systemic disease; inadequate
bone marrow reserves or organ function. The study was ap-
proved by the independent ethics committee, research ethics
board or institutional review board at each centre and com-
plied with the International Conference on Harmonisation’s
Harmonised Tripartite Guidelines for Good Clinical Practice,
the Declaration of Helsinki and local laws. All patients pro-
vided written informed consent.
Study design
This Phase I, open-label, Japanese, multicentre study was con-
ducted in two parts (Fig. 1). Part A was a dose-escalation
Fig. 1 AZD4547 Japanese Phase I study design. Part A was a dose-
escalation study with a 5- to 10-day washout period followed by bid
dosing. Part B was a dose-escalation study in patients with FGFR-
amplified tumours with an RP2D of 80 mg bid. *Cohort 4 dose was
based on PK modelling data and was consistent with the latest tolerated
exposures from AZD4547 bid dosing in Western patients [16], as well as
emerging safety data from Japanese patients (this study); †In schedule 2, it
was planned that dose assessment could extend over multiple cohorts;
however, no cohorts exceeded the 160 mg qd dosing level due to
emerging data from the study in Western patients and a decision from the
clinical project team. RP2D, recommended Phase II dose
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phase. Single oral dosing (40 mg; 80mg; 120mg) was follow-
ed by a 1-week washout period. Multiple oral dosing was
delivered in 21-day cycles according to two treatment sched-
ules: schedule one (40 mg twice daily [bid]; 80 mg bid;
120 mg bid) and schedule two (160 mg once daily [qd]).
Part B was an expansion phase that evaluated a recommended
dose (RD) of 80 mg bid in FGFR-amplified tumours. FGFR
amplification was determined by central fluorescence in situ
hybridization (FISH) testing of archival tumour samples. This
RDwas determined using both emerging data from Part A and
existing data from the study in Western patients
(NCT00979134) [16].
A ‘rolling six’ design was used, with a minimum of three
evaluable patients per cohort [33]. If one patient experienced a
dose-limiting toxicity (DLT), additional patients were enrolled
up to a maximum of six evaluable patients. DLTs were eval-
uated during the washout period and the first 21-day treatment
schedule. These were defined as any toxicity not attributable
to the disease under investigation, including haematological
toxicity of CTCAE grade ≥4, non-haematological toxicity of
CTCAE grade ≥3, and any other toxicity that was clinically
significant, did not respond to supportive care and resulted in
discontinuation of dosing. If two or more evaluable patients
experienced a DLT, this dosing level was considered as non-
tolerable. It was planned that the maximum tolerated dose
(MTD) would be defined either as the dosing level below
the non-tolerated dose or such that a dose between the non-
tolerated dose and the last tolerated dose may be investigated.
Patients who tolerated AZD4547 treatment and received clin-
ical benefit were permitted to continue treatment until they
experienced progressive disease or withdrew consent.
Study objectives
The primary objective of this study was to evaluate the safety
and tolerability of oral AZD4547 in Japanese patients with
advanced solid malignancies. Secondary objectives included
defining the MTD and/or a tolerable RD, characterizing the
PK properties following both single and multiple dosing of




Safety and tolerability were assessed during study treatment
and until 28 days after the final dose. Adverse events (AEs)
were evaluated according to CTCAE (version 4.0), and dose
interruptions and reductions were recorded. Laboratory find-
ings and vital signs were analysed. Cardiac monitoring (echo-
cardiogram [ECHO] and ECG) and ophthalmic assessments
were also conducted.
Pharmacokinetic assessments
Blood samples for PK analysis were collected pre-dose and at
defined intervals up to 96 h following single dosing, and up to
24 h following multiple dosing. Urine samples were also col-
lected during the 24 h after multiple dosing in order to perform
urinary PK assessments. For multiple dosing, the 80 mg bid
dosing level was evaluated using combined data from patients
in both Part A and Part B, as FGFR amplification status was
unlikely to have a significant impact on PK. Concentrations of
AZD4547 in human plasma and urine were determined using
a validated high-performance liquid chromatography–tandem
mass spectrometry method at PRA International (Assen,
The Netherlands). PK parameters were analysed by standard
non-compartmental methods using WinNonlin software
(Pharsight Corporation, Mountain View, CA, USA).
Efficacy
Tumour assessments were performed according to Response
Evaluation Criteria in Solid Tumors version 1.1 (RECIST
v1.1) at baseline, on day 21 of the first treatment cycle, then
every 6 weeks after the start of treatment for 12 weeks, and
thereafter every 12 weeks (±1 week) until discontinuation of
study treatment or withdrawal of consent.
Statistics
No formal hypothesis-led statistical analysis was performed.
Safety, tolerability, PK data and efficacy were summarized
using descriptive statistics. Analysis sets for safety and effica-
cy contained all patients who received ≥1 dose of AZD4547.




Between 5 November 2010 and 22 November 2012, 30
Japanese patients were enrolled in Part A of this study (male,
n=16; female, n=14) and four in Part B (male, n=3; female,
n=1). All patients received at least one dose of AZD4547 and
were evaluable for safety, PK, and efficacy analyses. A sum-
mary of patient characteristics is given in Table 1. The mean
age of patients was 62.3 years (range 30–78 years) in Part A
and 70.8 years (range 64–76 years) in Part B. The major pri-
mary tumour locations were lung (33.3% in Part A; 25.0% in
Part B), breast (16.7%; 25.0%), and stomach (13.3%; 50.0%).
The majority of patients (93.3%) in Part A and all patients in
Part B had metastatic disease, with the respiratory system and
lymph nodes as the most commonly reported disease sites. At
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entry into this study, most patients had received prior radio-
therapy (96.7% in Part A; 100% in Part B) and all had received
previous chemotherapy, with 26.7% and 25.0% of patients
having received ≥3 lines of previous chemotherapy in Parts
A and B, respectively.
Safety and tolerability
Dose escalations
During the dose-escalation phase in Part A, AZD4547 dosing
was escalated in three cohorts in schedule one (40 mg bid;
60 mg bid; 120 mg bid). Based on the emerging safety profile,
the safety review committee authorized the initiation of sched-
ule two, a once-daily dose, in a fourth cohort (160 mg qd).
However, based on emerging data from the study in Western
patients [16] and a decision from the clinical project team, the
qd dose regimen was not escalated to 240 mg.
No DLTs were observed across any of the four cohorts
examined and given the decision not to titrate beyond the
once-daily schedule of 160 mg qd, the MTD was not deter-
mined for Japanese patients in this study. Instead, the recom-
mended dose of 80 mg bid for assessment in Part B was
determined based on safety data from Part A of this study
Table 1 Patient demographics and baseline characteristics
AZD4547 dose
Part A Part B
40 mg bid 80 mg bid 120 mg bid 160 mg qd Total Part A 80 mg bid
(N= 3) (N = 6) (N= 6) (N = 15) (N= 30) (N= 4)
Sex, n (%)
Female 1 (33.3) 4 (66.7) 2 (66.7) 7 (46.7) 14 (46.7) 1 (25.0)
Male 2 (66.7) 2 (33.3) 4 (33.3) 8 (53.3) 16 (53.5) 3 (75.0)
Median age, years 49 63.5 61.5 66.0 63.5 71.5
(range) (41–73) (30–76) (47–76) (51–78) (30–78) (64–76)
WHO performance status, n (%)
0 3 (100) 5 (83.3) 3 (50.0) 7 (46.7) 18 (60.0) 2 (50.0)
1 0 (0) 1 (16.7) 3 (50.0) 8 (53.3) 12 (40.0) 2 (50.0)
Local/metastatic sites, n (%)
Local only 0 (0) 0 (0) 1 (16.7) 1 (6.7) 2 (6.7) 0
Local/metastatic 3 (100) 6 (100) 5 (83.3) 14 (93.3) 28 (93.3) 4 (100)
Common primary tumour types, n (%)
Bile duct 0 (0) 0 (0) 0 (0) 1 (6.7) 1 (3.3) 0 (0)
Bladder 0 (0) 0 (0) 0 (0) 1 (6.7) 1 (3.3) 0 (0)
Breast 0 (0) 4 (66.7) 0 (0) 1 (6.7) 5 (16.7) 1 (25.0)
Caecum 1 (33.3) 0 (0) 0 (0) 0 (0) 1 (3.3) 0 (0)
Colon 1 (33.3) 1 (16.7) 0 (0) 0 (0) 2 (6.7) 0 (0)
Colorectal 0 (0) 0 (0) 0 (0) 1 (6.7) 1 (3.3) 0 (0)
Lung 0 (0) 1 (16.7) 3 (50.0) 6 (40.0) 10 (33.3) 1 (25.0)
Oesophagus 0 (0) 0 (0) 0 (0) 1 (6.7) 1 (3.3) 0 (0)
Pancreas 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.3) 0 (0)
Rectal 0 (0) 0 (0) 0 (0) 1 (6.7) 1 (3.3) 0 (0)
Stomach 0 (0) 0 (0) 1 (16.7) 3 (20.0) 4 (13.3) 2 (50.0)
Thymus 1 (33.3) 0 (0) 0 (0) 0 (0) 1 (3.3) 0 (0)
Urachus 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.3) 0 (0)
Prior therapy, n (%)
Chemotherapy 2 (66.7) 6 (100) 6 (100) 15 (100) 29 (96.7) 4 (100)
Other systemic
anticancer therapy
2 (66.7) 2 (33.3) 1 (16.7) 6 (40.0) 11 (36.7) 1 (25.0)
Radiotherapy 3 (100) 6 (100) 6 (100) 15 (100) 30 (100) 4 (100)
Hormonal/immunotherapy 0 (0) 1 (16.7) 0 (0) 2 (13.3) 3 (33.3) 0 (0)
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alongside the data in Western patients [16]. No DLTs were
observed with the RD of 80 mg bid in Part B.
All patients had discontinued the study by the data cut-off
date (16 August 2013). The most common reasons for discon-
tinuation in Part Awere disease progression in 14/30 patients
(46.7%), AEs in 9/30 patients (30.0%; 80 mg bid, n= 3;
160 mg qd, n=6), and death in 1/4 patients (25.0%; 160 mg
qd). All patients (80 mg bid, n=4) in Part B discontinued
AZD4547 following disease progression.
Summary of AEs
Overall, 32/34 patients (94.1%) experienced at least one AE
following AZD4547 treatment (Table 2); the AEs of 30/34
patients (88.2%) were considered by the investigator to be
causally related to AZD4547. The most frequently reported
AEs (≥20%) in Part Awere dysgeusia in 14 patients (46.7%),
diarrhoea in 12 (40.0%), stomatitis in 12 (40.0%),
hyperphosphataemia in 11 (36.7%), dry mouth in 10
(33.3%), dry skin in nine (30.0%), nausea in eight (26.7%),
detachment of retinal pigment epithelium in seven (23.3%),
vomiting in six (20.0%), malaise in six (20.0%), nail
discolouration in six (20.0%), and pruritus in six (20.0%).
The most common AEs (≥50%) in Part B were dysgeusia in
three patients (75.0%) and stomatitis, hyperphosphataemia,
dry mouth, nausea, and decreased appetite, which were all
present in two patients each (50.0%). Three patients (10.0%)
experienced an AE of CTCAE grade ≥3 in Part A (80 mg bid);
these were judged to be causally related to the study treatment
in one patient (3.3%). Three patients (75.0%) experienced an
AE of CTCAE grade ≥3 in Part B; however, these AEs were
not deemed to be treatment related. Overall (N=34), the most
common CTCAE grade ≥3 AEs were neutropenia in three
patients (8.8%), nausea in two (5.8%), and decreased appetite
Table 2 Summary of AEs occurring in ≥20% of all patients, AEs of grade ≥3 occurring in ≥5% of all patients, and SAEs for each cohort
AZD4547 dose










Part A (N = 30)
80 mg bid
(N= 4)
Patients with AE of any grade, n (%) 3 (100) 6 (100) 6 (100) 14 (93.3) 29 (97.6) 4 (100)
Dysgeusia 0 (0) 2 (33.3) 5 (83.3) 7 (50.0) 14 (46.7) 3 (75.0)
Diarrhoea 0 (0) 2 (33.3) 5 (83.3) 5 (33.3) 12 (40.0) 1 (25.0)
Stomatitis 1 (33.3) 4 (66.7) 4 (66.7) 3 (20.0) 12 (40.0) 2 (50.0)
Hyperphosphataemia 0 (0) 1 (16.7) 3 (50.0) 7 (50.0) 11 (36.7) 2 (50.0)
Dry mouth 0 (0) 3 (50.0) 2 (33.3) 5 (33.3) 10 (33.3) 2 (50.0)
Dry skin 1 (33.3) 2 (33.3) 2 (33.3) 4 (26.7) 9 (30.0) 0 (0)
Nausea 1 (33.3) 2 (33.3) 1 (16.7) 4 (26.7) 8 (26.7) 2 (50.0)
Detachment of retinal pigment epithelium 0 (0) 0 (0) 0 (0) 7 (50.0) 7 (23.3) 1 (25.0)
Vomiting 0 (0) 2 (33.3) 2 (33.3) 2 (13.3) 6 (20.0) 1 (25.0)
Malaise 0 (0) 2 (33.3) 2 (33.3) 2 (13.3) 6 (20.0) 1 (25.0)
Decreased appetite 1 (33.3) 1 (16.7) 1 (16.7) 2 (13.3) 6 (20.0) 2 (50.0)
Patients with CTCAE grade ≥3 event, n (%) 0 (0) 3 (50.0) 0 (0) 0 (0) 3 (10.0) 3 (75.0)
Neutropenia 0 (0) 2 (33.3) 0 (0) 0 (0) 2 (6.7) 1 (25.0)
Nausea 0 (0) 2 (33.3) 0 (0) 0 (0) 2 (6.7) 0 (0)
Decreased appetite 0 (0) 1 (16.7) 0 (0) 0 (0) 1 (3.3) 2 (50.0)
Stomatitis 0 (0) 1 (16.7) 0 (0) 0 (0) 1 (3.3) 0 (0)
Pneumonia 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.3) 1 (25.0)
Increased alanine aminotransferase 0 (0) 1 (16.7) 0 (0) 0 (0) 1 (3.3) 0 (0)
Decreased appetite 0 (0) 1 (16.7) 0 (0) 0 (0) 1 (3.3) 0 (0)
Hypoglycaemia 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.3) 1 (25.0)
Patients with SAE grade ≥3 event, n (%) 0 (0) 0 (0) 2 (33.3) 0 (0) 2 (6.7) 1 (25.0)
Nausea 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.3) 0 (0)
Stomatitis 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.3) 0 (0)
Decreased appetite 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.3) 1 (25.0)
SAE serious adverse event
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in three (8.8%). Three SAEs were experienced by two patients
(6.7%) in Part A and one patient (25.0%) in Part B. All pa-
tients with SAEs required hospitalization. Only one SAE, de-
creased appetite and nausea, was deemed to be causally relat-
ed to AZD4547 treatment (Part A; 80 mg bid). Two further
SAEs, stomatitis (Part A; 80 mg bid) and decreased appetite
(Part B; 80 mg bid), were not considered to be causally related
to treatment with AZD4547. One death occurred during the
study period (160 mg qd) following disease progression; the
study investigators concluded that this death was not causally
related to AZD4547 treatment.
Dose interruptions and reductions
Nine patients (30.0%) in Part A reported dose interruptions
following AEs, and 13/30 patients (43.3%) experienced dose
reductions, of whom 12 (40.0%) had reductions following
AEs, most commonly detachment of retinal pigment epitheli-
um or other retinal disorders, as well as hyperphosphataemia
and dizziness. One patient (25.0%) in Part B had a dose inter-
ruption as a result of an AE of decreased appetite, and two
patients (50.0%) had dose reductions after reporting AEs of
retinal detachment, nausea, and hypoglycaemia. The mean
actual treatment duration was 80.1 days in Part A and
36.0 days in Part B. The mean relative dose intensity was
87% in Part A and 83.5% in Part B.
Dose discontinuation
In Part A, 9/30 patients (30.0%) had an AE leading to discon-
tinuation of the study drug, and these AEs were considered
causally related to the study drug by the investigator. None of
the patients in Part B had AEs leading to discontinuation.
Retinal events led to study-drug discontinuation in 7/34 pa-
tients (20.5%) and all patients recovered.
Other safety observations
Treatment-related increases in blood phosphate levels were
observed in 11 patients (36.7%) in Part A and two patients
(50.0%) in Part B, with median change in phosphate levels
from baseline ranging from –0.16 to 0.79 mmol/L in the
80 mg bid cohort (combined from Parts A and B) to –0.29
to 0.72 mmol/L in the 160 mg qd cohort. Time to onset ranged
from 9 to 24 days. All except one patient received treatment
with fosrenol in accordance with the management guidelines
for hyperphosphataemia and recovered. No clinically relevant
changes in vital or physical signs were observed. One patient
(120 mg bid) with a normal ECG at baseline experienced an
abnormal ECG with AZD4547 treatment; however, this was
not considered to be clinically relevant. Three patients expe-
rienced a decrease in left ventricular ejection fraction (LVEF)
of ≥10 percentage points and three patients experienced an
absolute LVEF value of <55%; however, no patients were
reported to have fulfilled both criteria simultaneously and,
consequently, these changes were not considered to be clini-
cally relevant. Grade 1 and 2 decreases in platelet counts were
observed in 13/30 patients (43.3%), and only in the 160 mg qd
cohort. All other clinical laboratory observations were com-
parable between dosing levels. A trend in mean-value increase
for transaminases and blood creatinine was observed, which
consisted mainly of a one-grade shift.
Pharmacokinetics
Following single dosing, AZD4547 plasma levels were quan-
tifiable across all investigated dosing levels. The mean plasma
concentration–time profiles for single and multiple dosing are
shown in Fig. 2. A summary of PK parameters is given in
Table 3. Median time to maximum plasma concentration
(tmax) ranged from 2.9 to 4.0 h across the dose levels of 40–
160 mg. After reaching maximum plasma concentration
(Cmax), AZD4547 concentrations declined biphasically, with
a mean terminal half-life (t1/2λz; ± standard deviation [SD])
ranging from 22.4 (±7.21) to 33.5 (±7.49) h. The ratio of the
area under the plasma concentration–time curve from time 0
to infinity (AUC) to that from time 0 to time of last measurable
concentration (AUC0–t) was >0.87, indicating that the sam-
pling scheme used had reliably captured the plasma concen-
tration–time profiles. The percentage coefficient of variation
(CV%) values for Cmax and AUC were 54.0–142% and 53.3–
117%, respectively, across the dosing levels. Dose-normalized
Cmax and AUC values were 9.58–21.4 ng/mL and 0.61–
1.35 h · ng/mL, respectively, for the dosing levels tested.
Mean (±SD) oral clearance (CL/F) ranged from 57.8 (±27.3)
to 116 (±77.0) L/h and was independent of dose across the
dosing range of 80–160 mg.
AZD4547 plasma levels were quantifiable across all levels
and time points for multiple dosing, and steady state (ss) was
reached by day 8. The CV% range for Css,max was 23.0–
65.9%, and the CV% range for AUCss was 10.5–61.0%.
Dose-normalized values for Css,max and AUCss were 1.60–
3.41 ng/mL and 11.4–29.7 h · ng/mL across the different mul-
tiple dosing levels. Median tmax ranged from 2.9 to 4.0 h post-
dose, in line with the data from single dosing. Mean (±SD)
CLss/F ranged from 37.9 (±19.9) to 87.9 (±9.37) L/h, which
were lower than the CL/F values for single doses. The mean
(±SD) accumulation ratio (RAC; ratio of multiple-dose AUCss
to single-dose AUC0–12h) was 3.34 (±1.98), 4.87 (±2.42), and
5.34 (±5.43), respectively, for 40 mg, 80 mg, and 120 mg bid
dosing. The mean (±SD) value of RAC (ratio of multiple-dose
AUCss to single-dose AUC0–24h) for the 160 mg qd cohort
was 2.42 (±1.56). The mean (±SD) values of temporal change
(Tc; ratio of multiple-dose AUCss to single-dose AUC) were
1.37 (±1.01), 1.75 (±0.86), 1.61 (±1.41) and 1.37 (±0.88),
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respectively, for 40 mg, 80 mg, 120 mg bid and 160 mg qd
dosing.
Urinary PK data were available for 27 patients (25/30
patients in Part A; 2/4 patients in Part B). The mean (±SD)
steady-state fraction of the AZD4547 dose excreted in
urine (fe) was 3.92% (±0.828%), 3.66% (±1.25%), 4.13%
(±1.68%) and 3.78% (±2.48%) for 40 mg, 80 mg, 120 mg
bid and 160 mg qd dosing, respectively, suggesting that
urinary excretion of AZD4547 is dose independent. Mean
(±SD) steady-state renal clearance (CLR) values were var-
iable at 3.23 (±0.58), 1.25 (±0.43), 2.32 (±0.63) and 1.38
(±0.59) L/h, respectively, for 40 mg, 80 mg, 120 mg bid
and 160 mg qd dosing, but showed no dose-dependency
trend.
Preliminary efficacy
Complete responses and partial responses, according to
RECIST v1.1, were not observed; however, stable disease
(≥4 weeks’ duration) was observed in 21 patients (70.0%;
40 mg bid, n = 3; 80 mg bid, n = 3; 120 mg bid, n = 5;
160 mg qd, n = 10) in Part A, with one patient (25.0%;
80mg bid) continuing to experience stable disease at 10weeks
in Part B. Except for one patient in Part A with a non-
evaluable response, all remaining patients showed disease
progression. Post-baseline target lesion measurements were
available in 25/30 patients in Part A and all patients in Part
B; the median percentage change in the sum of the diam-
eters was 5.9% (range –6.8% to 48.9%) in Part A and
3.0% (range –16.3% to 23.4%) in Part B.
Discussion
The FGFR pathway is involved in key cellular processes
necessary for survival and differentiation. Accordingly, ab-
errant FGFR signalling has significant oncogenic potential.
This Phase I study is the first to evaluate the safety and
tolerability of AZD4547 in a population of Japanese pa-
tients with advanced solid malignancies for which no stan-
dard or effective treatment exists. The characteristics of
this study population were comparable to those of the
intended target population for AZD4547.
Fig. 2 Plasma concentration–
time profiles of AZD4547 after
a single dosing and b multiple
dosing. Geometric mean plasma
concentrations are shown against
time for the dosing levels 40 mg
bid, 80 mg bid (combined from
cohorts dosed at the 80 mg bid
level across both Parts A and B),
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Overall, AEs during AZD4547 treatment were generally mild
to moderate and reversible upon withdrawal of treatment, as
has been observed previously [16]. No DLTs were observed in
our study and the drug was not titrated to an MTD as a result
of emerging safety data from the Phase I study conducted in
Western patients [16]. In the study in Western patients,
AZD4547-treatment-related DLTs of renal failure, elevated
liver enzymes, hyperphosphataemia, and mucositis were ob-
served at the dose range 20–200 mg bid [16]. The absence of
causally related DLTs in our Japanese population may, there-
fore, be explained by the lower dosing levels, despite body
mass in the Japanese patients being smaller than in the
Western patients. An RD of 80 mg bid was determined based
on the combined safety data from our study and from the study
in Western patients [16]; this RD was evaluated during the
expansion phase.
Results of the expansion phase showed that the RD of
80 mg bid was well tolerated in Japanese patients with
FGFR-amplified tumours (as determined by FISH).
Consistent with data fromWestern patients, the most common
AEs in our study were gastrointestinal disorders, dryness,
hyperphosphataemia, and eye disorders and included diar-
rhoea, stomatitis, dry mouth and skin, nausea, dysgeusia,
and detachment of retinal pigment epithelium [16, 34, 35].
Similar safety findings have been reported for other selective
FGFR receptors [36–38]. One of the safety concerns for se-
lective FGFR inhibitors from preclinical toxicity studies has
been hyperphosphataemia, caused by loss of FGF23 signal-
ling, resulting in calcification of tissues [2, 32]. All phosphate-
related events in our study were of CTCAE grade ≤3 and were
controllable with therapeutic interventions. Taken together
with available clinical data from AZD4547 and other FGFR
inhibitors, this indicates that hyperphosphataemia with FGFR
inhibitors is generally manageable in humans [16, 37].
Pharmacokinetics
The PK findings were generally consistent betweenAZD4547
single and multiple dosing. Following bid dosing in three
cohorts (40 mg; 80 mg; 120 mg) and qd dosing in one cohort
(160 mg), steady state was achieved by day 8, and the accu-
mulation ratio was consistent with the prediction from single-
dose t1/2λz. Dose-normalized PK parameters for single and
multiple doses were similar across all dosing levels; however,
the small number of patients in each cohort and the variability
between plasma concentration–time plots make dose propor-
tionality difficult to establish. Tc tended to be close to or
slightly higher than unity, suggesting that there were no nota-
ble time-dependent changes in PK upon multiple dosing. A
relatively small proportion of AZD4547 was excreted in the
urine unchanged (3.8–4.1% of the dose), suggesting that
urinary excretion may be a minor route of AZD4547 elimina-
tion if AZD4547 absorption is good in humans. The results
reported here are the first published PK data for AZD4547 in
any patient population, and it would therefore be interesting to
compare our PK findings with subsequent PK data that may
emerge from the ongoing clinical development of AZD4547.
Efficacy and comparisons with other FGFR inhibitors
The best response following AZD4547 treatment in this study
was stable disease for ≥4 weeks in 70% of patients, with one
BC patient experiencing stable disease at 10 weeks. Previous
efficacy data from the Western population showed a best re-
sponse of PR (80 mg bid) for ≥12 weeks in one patient with
FGFR1-amplified squamous NSCLC [16]; stable disease was
also observed in 4/21 patients (19%), three of whom (75%)
had confirmed FGFR amplification.
Efficacy data from clinical studies of other selective FGFR
inhibitors have also been reported. In a Phase I study of
BGJ398 (Novartis), PRs were observed in 2/17 evaluable pa-
tients with lung squamous cell carcinoma, with durations of 8
and 3 months [39]. It is important to note that this study popu-
lation was selected on the basis of their FGFR amplification
status. In an extended cohort of the same study, 8/25 patients
with previously treated advanced/metastatic urothelial carcino-
ma (UC) and FGFR3 alterations had PRs, with one uncon-
firmed complete response [40]. Published findings from a
Phase I trial of the selective FGFR inhibitor JNJ-42756493
(Johnson& Johnson) have shown PRs in 4/23 evaluable patients
[36]. All patients demonstrating a PR had FGFR2 or FGFR3
translocations, and tumour types were reported as glioblastoma,
UC, and endometrial cancer. Phase II studies of FGFR inhibitors
are ongoing in different tumour types harbouring FGFR gene
alterations. These include assessment of AZD4547 at the RD
of 80 mg bid in FGFR2-amplified GC and FGFR1-amplified
BC (NCT01457846; NCT01795768) [35, 41], BGJ398 in pa-
tients with advanced FGFR-altered colangiocarcinoma [38], and
JNJ-42756493 in patients with metastatic or unresectable UC
with FGFR gene alterations [42]. Selective FGFR inhibitors
may also have potential in combination with other agents [43,
44].
Further investigation is required to establish the treatment
settings in which this new class of drugs can provide the most
meaningful clinical benefit. The initial expectation was that
selection of patients by screening for FGFR amplification
may identify responsive patients; however, patients with
FGFR gene amplification have responded inconsistently to
FGFR inhibitors [16, 45]. A key focus for development of
selective FGFR inhibitors will therefore be to determine how
aberrations in FGFR may be predictive of a response to treat-
ment and incorporate appropriate predictive biomarkers into
patient stratification. Taking this into consideration, the ongo-
ing Phase Ib BISCAY biomarker-directed multidrug umbrella
Invest New Drugs
study (NCT02546661) will allocate patients to AZD4547 treat-
ment based on FGFR3 mutations or FGFR1–3 fusions [46].
Several non-selective, multi-targeted TKIs have been li-
censed that can act as FGFR inhibitors, including pazopanib,
lenvatinib, ponatinib, regorafenib, and nintedanib. In addition
to FGFRs, these compounds have activity against a wide range
of targets, including VEGFR1–3 and platelet-derived growth
factor [47, 48], and have demonstrated clinical benefit for the
treatment of several tumour types, such as renal cell carcinoma
[23, 24], soft tissue sarcoma [49, 50], thyroid cancer [51], met-
astatic colorectal cancer [52], chronic myeloid leukaemia [53]
and NSCLC [54, 55]. However, cardiac toxicity has been re-
ported as a widespread AE with multi-targeted TKIs and is
thought to be a dose-dependent, on-target effect related to the
inhibition of VEGFR [56]. It is therefore useful to note that no
significant cardiac toxicity was reported with AZD4547 treat-
ment during this study, and cardiac toxicity has not been
highlighted as a concern from previous studies with selective
FGFR inhibitors [16, 35, 37, 39].
Summary
AZD4547 was well tolerated in this Phase I study and no
DLTs were reported. Based on safety data from Part A, and
taking into account previous data in Western patients [16], the
recommended dose was determined as 80 mg bid. Further
investigation is required to establish the treatment settings in
which this new class of drugs can provide the most meaning-
ful clinical benefit.
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